Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo Rainbow SET® Pulse CO-Oximetry, and new Masimo noninvasive and continuous total hemoglobin (SpHb™) monitoring technology. The recent introduction of the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw is expected to open new markets and significantly expand the companys growth opportunities.
For more than 20 years now, Masimo has been focused on a singular missionto create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making.